#ASH24: Late-phase trials and real-world studies in AML

To update you on the exciting content presented at the 66th ASH Annual Meeting and Exposition, December 7–10, 2024, San Diego, US, we have collated our social media coverage. Catch up here with our live social media relating to late-phase trials and real-world studies in acute myeloid leukemia.  

CONGRESS | #ASH24 | PRESENTATION@ShaiShimony @DanaFarber highlights results from a post hoc analysis of the phase III CPX-351-301 trial.
Results suggest that the benefit of CPX-351 vs 7+3 chemotherapy is driven by the presence of AML-MR defining mutations.
Follow our live feed… pic.twitter.com/oHSiw6TsGA

— AML Hub (@AML_Hub) December 7, 2024

CONGRESS | #ASH24 | POSTER
Mark Levis, @hopkinskimmel, discussed results from an exploratory analysis of the phase III QuANTUM-first trial (NCT02668653) evaluating quizartinib as a post-consolidation single-agent maintenance treatment in newly diagnosed patients with FLT3-ITD+… pic.twitter.com/zdVWxyTS9H

— AML Hub (@AML_Hub) December 9, 2024

CONGRESS | #ASH24 | PRESENTATION
Daniel J. DeAngelo @DanaFarber presents results from a phase III trial assessing uproleselan with chemotherapy vs chemotherapy alone in patients with R/R AML.
Although the primary endpoint of OS was not met, results provide evidence of the… pic.twitter.com/cWwwcddy7z

— AML Hub (@AML_Hub) December 9, 2024

CONGRESS | #ASH24 | PRESENTATION
Johannes Schetelig @DKMS_SciMed @Medizin_TUD presents long-term follow-up results from the ASAP trial.
Results show no survival advantage for remission induction prior to allo-HSCT vs immediate allo-HSCT for patients with AML and poor response… pic.twitter.com/am7FZRrBW7

— AML Hub (@AML_Hub) December 9, 2024

CONGRESS | #ASH24 | PRESENTATION
Mark Levis, @hopkinskimmel, discussed post-hoc analysis findings from the phase III QuANTUM-First trial (NCT02668653) evaluating the impact of baseline gene mutations on quizartinib efficacy in patients with FLT3-ITD–positive newly diagnosed AML… pic.twitter.com/pFC6yJM3MI

— AML Hub (@AML_Hub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Todd Cooper, @seattlechildren, presented findings from the phase III COG AAML 1831 trial comparing standard induction therapy to CPX-351 + gemtuzumab ozogamicin in children without FLT3m AML (N=721). The 2-year EFS from study entry was… pic.twitter.com/AXPfKFCIAG

— AML Hub (@AML_Hub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Brenda Gibson, @RHCGlasgow, presented findings from the phase III MyeChild 01 trial investigating gemtuzumab ozogamicin in children with newly diagnosed AML (N=515). Overall, 2-year EFS was 70% and OS was 88%. Three doses of GO vs 1 dose provided… pic.twitter.com/tz8A6shzLD

— AML Hub (@AML_Hub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Agnieszka Wierzbowska, @umedlodz, shared results from the phase III PALG-AML1/2016 trial (NCT03257241) comparing the efficacy and safety of two standard induction therapies: daunorubicin 90 mg/m2 + AraC (DA-90) vs daunorubicin 60 mg/m2 + AraC +… pic.twitter.com/JNcZ1pLJUn

— AML Hub (@AML_Hub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Zinan Feng from Nanfang Hospital, Southern Medical University, shared findings from a phase III trial comparing high-dose cytarabine + idarubicin (IA3+3) vs high-dose cytarabine (HDAC) as first consolidation therapy in patients with AML in first… pic.twitter.com/dLu3a1ktZ6

— AML Hub (@AML_Hub) December 10, 2024

CONGRESS | #ASH24 | POSTER
Jianxiang Wang, @PKU1898, presented a post-hoc analysis of the phase III ADMIRAL and COMMODORE trials, investigating timing of response to gilteritinib in patients with R/R FLT3-mutated AML. Among 205 CRc responders, around 90% achieved remission within… pic.twitter.com/DkD92LNlrU

— AML Hub (@AML_Hub) December 9, 2024

CONGRESS | #ASH24 | POSTER@drpramilak, @KingsCollegeNHS, presents a retrospective observational study on treatment patterns and clinical outcomes with oral azacitidine maintenance therapy in real-world patients with AML in Germany (n=106) and England (n=107). Median OS and rwRFS… pic.twitter.com/T4tOdcKJwI

— AML Hub (@AML_Hub) December 8, 2024

CONGRESS | #ASH24 | POSTER@KatieLaiMD_MPH, @PennMedicine, presents a comparative analysis of olutasidenib vs ivosidenib in patients with IDH1-mutated AML who were R/R to a venetoclax-based regimen. The CRc rate was significantly higher with olutasidenib vs ivosidenib in analysis… pic.twitter.com/G7M2mrub8v

— AML Hub (@AML_Hub) December 8, 2024